For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
Scope of the Report:
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
The worldwide market for Artificial Pancreas Devices Systems is expected to grow at a CAGR of roughly 13.8% over the next five years, will reach 120 million US$ in 2024, from 56 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Artificial Pancreas Devices Systems in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Medtronic
- Bigfoot Biomedical
- Beta Bionics
- Admetsys
- Insulet
- Tandem Diabetes Care
- Defymed
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Threshold Suspended Device Systems
- Hybrid Closed-loop APDS
- Other Systems
Market Segment by Applications, can be divided into
- Hospitals
- Clinics
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Artificial Pancreas Devices Systems product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Artificial Pancreas Devices Systems, with price, sales, revenue and global market share of Artificial Pancreas Devices Systems in 2017 and 2018.
Chapter 3, the Artificial Pancreas Devices Systems competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Artificial Pancreas Devices Systems breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Artificial Pancreas Devices Systems market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Artificial Pancreas Devices Systems sales channel, distributors, customers, research findings and conclusion, appendix and data source.